Galectin Therapeutics Inc. (GALT)

[bradfor123]

this is what I found February 5
sounds like from what I read below if all goes well end of 2016 phase 3 then I gather from that we are looking at towards end of 2018 approval
if it works well , is that right ? look I hope I am wrong I want to this to work probably more than most here as besides the money factor I have very close family members with advanced fibrosis desperate for something to look forward to .

Other than metastatic melanoma, GR-MD-02 is also studied in phase I for the treatment of nonalcoholic steatohepatitis (NASH) with advanced fibrosis. NASH is also known as fatty liver disease. Galectin Therapeutics completed enrolling patients in the first cohort of the phase I study on GR-MD-02 on Jan 13, 2014. Galectin Therapeutics might start a phase II study in late 2014 or early 2015 based on phase I study results and expects phase II top-line data in the first half of 2016 depending on the design of the study.